Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Methotrexate May Mitigate Inflammatory Bone Disease Note Experts at the ACR/ARHP Winter Rheumatology Symposium

Kimberly Retzlaff  |  Issue: April 2014  |  April 2, 2014

These antiinflammatory effects can be stymied, however. Caffeine and theophylline are adenosine-receptor blocking agents, Dr. Cronstein cautioned. They can “completely reverse” the antiinflammatory effects of methotrexate.

Inflammatory Osteolysis in Prosthesis Loosening

Adenosine-related mechanisms and axonal guidance proteins (i.e., Sema4D, netrin-1) may also be important in treating osteolysis in prosthesis loosening. Approximately 800,000 prosthetic joints are implanted annually in the U.S., Dr. Cronstein said. Despite changes in prostheses and surgical techniques, there has been no reduction in the rates of surgical revision—as many as 25% of patients undergo removal and replacements of the prosthesis. Inflammation caused by wear particles and osteoclast-mediated bone erosion are major contributors to prosthesis failure.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Laboratory studies show that adenosine receptors suppress Sema4D expression by osteoclasts. This is important, Dr. Cronstein noted, because Sema4D is highly expressed in periprosthetic soft tissue in patients who require prosthesis revision. Netrin-1 is similarly overexpressed in this case.

Stimulation of adenosine A2A receptors diminishes netrin-1 expression during wear particle–induced bone resorption. Stimulation of A2A can also suppress inflammatory bone disease by inhibiting osteoclast formation and function, stimulating interleukin (IL) 10 and osteoprotegerin expression, diminishing RANKL expression and diminishing wear particle–induced osteolysis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Methotrexate-induced adenosine specifically diminishes arthritis-associated bone disease, and because of this mechanism, it may also be a potential therapy for mediating the inflammatory osteolysis in prosthesis loosening. According to Dr. Cronstein, the positive effects of methotrexate due to its A2A receptor–mediated mechanism are that it diminishes wear particle–induced osteolysis and wear particle–induced suppression of bone formation.

Dr. Cronstein discussed recently published research that he and his colleagues conducted, showing additional potential for A2A in mitigating osteolysis.2 The researchers concluded, “These results in mice suggest that site-specific delivery of an adenosine [A2A receptor] agonist could enhance implant survival, delaying or eliminating the need for revision arthroplastic surgery.”

In their animal study, the researchers noted that applying an adenosine A2A agonist inhibits wear particle–induced bone loss, diminishes wear particle–induced inflammation, reduces the number of osteoclasts in treated bone and restores bone formation.


Kimberly J. Retzlaff is a medical journalist based in Denver.

References

  1. Fukuda T, Takeda S, Xu R, et al. Sema3A regulates bone-mass accrual through sensory innervations. Nature. 2013;497(7450):490–493.
  2. Mediero A, Frenkel SR, Wilder T, et al. Adenosine A2A receptor activation prevents wear particle-induced osteolysis. Sci Transl Med. 2012;4:135ra65.

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsDrug UpdatesMeeting ReportsOsteoarthritis and Bone DisordersOther Rheumatic ConditionsRheumatoid Arthritis Tagged with:ACR/ARHPAdenosineanti-inflammatorybonedrugMethotrexateOsteoarthritispatient careRheumatoid arthritisrheumatologist

Related Articles

    Sensory Nerves May Be Key for Osteoporosis

    September 10, 2013

    Sensory nerves have an essential role in bone remodeling. In particular, semaphorin 3A (Sema3A) regulates bone remodeling by modulating sensory nerve development. (posted Sept. 9, 2013)

    Old Drugs Can Learn New Tricks

    November 1, 2011

    Methotrexate and its mechanism of action

    A Duet of Bone and the Immune System

    July 12, 2011

    Examining emerging perspectives in osteoimmunology

    New Treatments Needed to Prevent Fractures in Osteoporosis

    June 1, 2014

    Current therapies target pathways of bone remodeling, but rheumatologists say a better understanding of the mechanisms of bone resorption, formation is needed to make an impact

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences